Thursday 16 October, 2025
Objectives: Selpercatinib, a first-in-class highly selective and potent rearranged during transfection (RET) kinase inhibitor with central nervous system activity, is…
Read moreAbstracts
Population pharmacokinetics of selpercatinib in patients with an advanced solid tumor, including RET fusion-positive NSCLC, RET-mutant MTC, and other tumors with increased RET activity
Thursday 16 October, 2025
Objectives: Selpercatinib, a first-in-class highly selective and potent rearranged during transfection (RET) kinase inhibitor with central nervous system activity, is…
Read morePopulation pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV and TB
Thursday 16 October, 2025
Introduction/Objectives Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is recommended as the first-line treatment for people living with…
Read moreComparison of performances of the open-source R package “nlmixr” vs. Monolix for population pharmacokinetics of continuous infusion meropenem in patients with onco-hematological malignancies
Thursday 16 October, 2025
Introduction Meropenem is a carbapenem used for empirical escalation therapy of onco-hematological patients with febrile neutropenia who are at risk…
Read moreDose Reduction and Population Pharmacokinetics of Lopinavir/ritonavir with and without Rifampin in Thai HIV-infected patients
Thursday 16 October, 2025
Introduction/Objectives: Lopinavir/Ritonavir (LPV/r) is an alternative drug in HIV-1 treatment when the first-line drugs cannot be used [1]. Currently, the…
Read moreComparison of PK models using normal and log-transformed scale data
Thursday 16 October, 2025
Introduction: Pharmacometric modelers usually choose on what form of data to use: normal scale or natural log-transformed data. While it is…
Read moreModel-integrated bioequivalence method for highly variable drugs with long half-life: a simulation study comparing complete washout and incomplete washout designs
Thursday 16 October, 2025
Objectives: An in vivo bioequivalence (BE) study with pharmacokinetic (PK) endpoints may be recommended to support the conclusion of therapeutic…
Read moreImpact of Imbalanced Baseline Responses among Dose Levels in the Exposure-Response Analysis by Nonlinear Mixed-Effect Modeling
Thursday 16 October, 2025
Introduction: Dose-ranging clinical studies can encounter imbalanced baseline responses among the groups of subjects testing different dose levels of a drug,…
Read moreThe International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology (ISoP QSP SIG): Recent Developments and Future Vision
Thursday 16 October, 2025
Objectives: The use of Quantitative Systems Pharmacology (QSP) as part of the drug development process just keeps growing over the…
Read morePopulation pharmacokinetic meta-analysis and dosing recommendation of meropenem in critically ill patients receiving continuous renal replacement therapy
Thursday 16 October, 2025
Introduction: The pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy (CRRT) is complicated. The volume of…
Read more